Wells Fargo & Company Aravive, Inc. Transaction History

Wells Fargo & Company

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.11 - $0.22 $12 - $25	114 Added 0.5%	22,811 $2,000
Q3 2023 Nov 13, 2023	SELL	$0.11 - $1.76 $2 - $33	-19 Reduced 0.08%	22,697 $2,000
Q2 2023 Aug 15, 2023	BUY	$1.25 - $1.92 $11 - $17	9 Added 0.04%	22,716 $28,000
Q1 2023 May 12, 2023	BUY	$1.29 - $2.46 $3 - $7	3 Added 0.01%	22,707 $45,000
Q4 2022 Feb 13, 2023	BUY	$1.2 - $1.83 $109 - $166	91 Added 0.4%	22,704 $29,000
Q3 2022 Nov 14, 2022	SELL	$0.61 - $1.03 $8 - $14	-14 Reduced 0.06%	22,613 $18,000
Q2 2022 Aug 12, 2022	BUY	$0.93 - $1.9 $53 - $110	58 Added 0.26%	22,627 $22,000
Q1 2022 May 16, 2022	BUY	$1.85 - $2.75 $4,626 - $6,877	2,501 Added 12.46%	22,569 $43,000
Q4 2021 Feb 14, 2022	BUY	$2.19 - $4.07 $2 - $4	1 Added 0.0%	20,068 $44,000
Q3 2021 Nov 15, 2021	BUY	$3.67 - $5.8 $2,675 - $4,228	729 Added 3.77%	20,067 $74,000
Q2 2021 Aug 16, 2021	SELL	$4.65 - $6.42 $154,868 - $213,818	-33,305 Reduced 63.27%	19,338 $116,000
Q1 2021 May 13, 2021	BUY	$5.11 - $9.24 $13,091 - $23,672	2,562 Added 5.12%	52,643 $347,000
Q4 2020 Feb 09, 2021	BUY	$4.36 - $6.51 $53,920 - $80,509	12,367 Added 32.79%	50,081 $282,000
Q3 2020 Nov 05, 2020	BUY	$4.7 - $12.06 $39,536 - $101,448	8,412 Added 28.71%	37,714 $178,000
Q2 2020 Aug 13, 2020	BUY	$5.18 - $14.81 $48,997 - $140,087	9,459 Added 47.67%	29,302 $341,000
Q1 2020 May 14, 2020	BUY	$3.5 - $13.77 $69,450 - $273,238	19,843 New	19,843 $114,000

28.1K

Ticker ARAV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,518,300
Description
Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.